drugset / Trial / NCT04679415
Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Explore the efficacy and confirm the safety of the concomitant administration of the standard of care and hzVSF-v13 in patients with COVID-19 infection
Timeline
- Start
- 2020-12-17
- Primary completion
- 2021-08-19
- Completion
- 2021-08-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Burfiralimab | Monoclonal antibody | 100 mg | Intravenous |
| Subject | Burfiralimab | Monoclonal antibody | 200 mg | Intravenous |